Abstract
Interim Analysis of a Phase II Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with Azacitidine in Advanced Myelodysplastic Syndrome (MDS)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have